Holen Sie sich die Stockscreener-App
53.97
3.62%
-2.03
Handel nachbörslich:
54.00
0.03
+0.06%
Schlusskurs vom Vortag:
$56.00
Offen:
$56
24-Stunden-Volumen:
1.77M
Relative Volume:
1.15
Marktkapitalisierung:
$8.26B
Einnahmen:
$700.35M
Nettoeinkommen (Verlust:
$461.90M
KGV:
18.81
EPS:
2.8696
Netto-Cashflow:
$-14.19M
1W Leistung:
-2.53%
1M Leistung:
-3.37%
6M Leistung:
+57.35%
1J Leistung:
+54.77%
1-Tages-Spanne:
$53.66
$56.24
1-Wochen-Bereich:
$53.36
$56.83
52-Wochen-Spanne:
$26.76
$59.30
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
53.97 | 8.26B | 700.35M | 461.90M | -14.19M | 2.8696 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2024-10-29 | Eingeleitet | TD Cowen | Buy |
| 2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
| 2023-06-26 | Fortgesetzt | Jefferies | Buy |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-04-25 | Eingeleitet | Jefferies | Buy |
| 2017-03-06 | Bestätigt | FBR & Co. | Outperform |
| 2016-10-06 | Fortgesetzt | Brean Capital | Buy |
| 2016-05-27 | Eingeleitet | SunTrust | Buy |
| 2015-12-01 | Eingeleitet | FBR Capital | Outperform |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-19 | Bestätigt | Brean Capital | Buy |
| 2014-12-11 | Bestätigt | ROTH Capital | Buy |
| 2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - Zacks Investment Research
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know - TradingView
Thermo Fisher to Report Q3 Earnings: What's in the Cards? - Zacks Investment Research
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis - BioSpace
TG Therapeutics (TGTX) Reports Five-Year Study Showing BRIUMVI's - GuruFocus
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis - Business Wire
High Growth Tech Stocks To Watch In US October 2026 - Simply Wall Street
How TG’s MS Data Wave At MSToronto2026 At TG Therapeutics (TGTX) Has Changed Its Investment Story - Yahoo Finance
TG Therapeutics (TGTX) Stock May Be Undervalued Despite Fresh Newsflow - Yahoo Finance
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026 - BioSpace
TG Therapeutics (TGTX) to Present Phase 1 Azer-cel Data and BRIU - GuruFocus
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026 - Business Wire
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo Finance
TG Therapeutics, Inc. (TGTX) Stock forecasts - Yahoo Finance Singapore
TG Therapeutics (NASDAQ:TGTX) Emerges as an Affordable Growth Play in Biotech - ChartMill
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo Finance
TG Therapeutics, Inc. (TGTX) Stock forecasts - Yahoo Finance Australia
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo Finance
TG Therapeutics, Inc. (TGTX) Stock forecasts - Yahoo Finance Australia
After tax other income/expense of TG Therapeutics, Inc. – HAN:NKB2 - TradingView
TG Therapeutics, Inc. Revenue Breakdown – HAN:NKB2 - TradingView
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm - Morningstar
TG Therapeutics (NasdaqCM:TGTX) Stock Forecast & Analyst Predictions - Simply Wall Street
TG Therapeutics, Inc. (TGTX) Stock Forecasts - Yahoo! Finance Canada
TG Therapeutics, Inc. (TGTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
TG Therapeutics (NASDAQ:TGTX) Combines Strong Growth With a Tight Technical Breakout Setup - ChartMill
TG Therapeutics, Inc. (TGTX) Stock Analysis: Exploring a 22.59% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
TG Therapeutics Inc (TGTX) Stock Price Today: $56.87 - Pluang
TG Therapeutics Inc (TGTX) Stock Price, Quote, News & History - benzinga.com
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share - Yahoo Finance
TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share - TradingView
TG Therapeutics (TGTX) Could Be 19% Undervalued After Its Recent Rebound - Yahoo Finance
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
TG Therapeutics (NASDAQ: TGTX) director plans $274,794.08 stock sale - Stock Titan
TG Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference | TGTX Stock News - quiverquant.com
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - TG Therapeutics
TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
TG Therapeutics at Cantor conference: briumvi gains momentum By Investing.com - Investing.com Canada
TG Therapeutics at Cantor conference: briumvi gains momentum By Investing.com - Investing.com India
TG Therapeutics at Cantor conference: briumvi gains momentum By Investing.com - Investing.com UK
TGTX: BRIUMVI targets $1B+ run rate, expanding with subQ and simplified dosing, backed by strong IP - TradingView
TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth - Eastern Progress
TG Therapeutics, Inc. (TGTX) Stock Analysis: Unveiling a 24.52% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
TGTX Stock On Track For Best Day In 3.5 Months Amid Fresh Buyout Rumors - Stocktwits
TG Therapeutics to Participate in the Cantor Global Healthcare Conference - manilatimes.net
TG Therapeutics to Participate in the Cantor Global Healthcare Conference - TG Therapeutics
TG Therapeutics to Participate in the Cantor Global Healthcare Conference - GlobeNewswire
B. Riley Securities Remains a Buy on TG Therapeutics (TGTX) - The Globe and Mail
(TGTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tg Therapeutics Inc-Aktie (TGTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Charney Laurence N | Director |
Sep 10 '26 |
Proposed Sale |
54.96 |
5,000 |
274,794 |
0 |
| Echelard Yann | Director |
Nov 24 '25 |
Sale |
32.57 |
5,000 |
162,850 |
223,816 |
| Echelard Yann | Director |
Nov 24 '25 |
Proposed Sale |
32.57 |
5,000 |
162,850 |
0 |
2.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):